Menopause Competence
A structured, evidence-based course on the menopause transition — built on current professional-society guidance.
Menopause is something roughly half the population will live through, yet it remains undertaught and undertreated. Surveys of U.S. obstetrics and gynecology residency programs found that only about one in three reported any menopause curriculum at all. This course is designed to close part of that gap — for the people living it and the clinicians caring for them.
There are two tracks. They cover the same biology but are written for different readers and tested at different depths. Pick the one that fits you. You can switch any time.
How it works
Each track has 10 modules. Read the module, then answer a short knowledge check to mark it complete. A progress bar tracks where you are. When all ten are done, you reach a completion screen with links to the interactive tools that put each topic into practice. Nothing you do here is stored or sent anywhere — progress lives only in this browser session.
What this course is built on
Every clinical figure in this course traces to a specific, published source. The evidence base, in Vancouver format:
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028. Primary U.S. society guidance on who should be offered hormone therapy, formulations, and the timing hypothesis.
- The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. doi:10.1097/GME.0000000000002200. Graded recommendations for non-hormonal management of vasomotor symptoms.
- Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10. Menopause. 2012;19(4):387-395. doi:10.1097/gme.0b013e31824d8f40. PMID 22343510. STRAW+10 — the gold-standard staging system for reproductive aging.
- Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-539. doi:10.1001/jamainternmed.2014.8063. PMID 25686030. SWAN cohort — median total VMS duration of 7.4 years; longest in Black women.
- Portman DJ, Gass ML; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy. J Sex Med. 2014;11(12):2865-2872. PMID 25160739. Consensus that introduced the term GSM and reframed local therapy.
- Cho L, Kaunitz AM, Faubion SS, et al. Rethinking menopausal hormone therapy: for whom, what, when, and how long? Circulation. 2023;147(7):597-610. doi:10.1161/CIRCULATIONAHA.122.061559. Contemporary cardiology synthesis of the timing hypothesis.
- Lederman S, Ottery FD, Cano A, et al. Fezolinetant for moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091-1102. doi:10.1016/S0140-6736(23)00085-5. PMID 36924778. Pivotal trial of the first NK3-receptor antagonist for VMS.
- Pinkerton JV, Simon JA, Joffe H, et al. Elinzanetant for the treatment of vasomotor symptoms associated with menopause: OASIS 1 and 2 randomized clinical trials. JAMA. 2024;332(16):1343-1354. Pivotal trials of the dual NK1/NK3-receptor antagonist.
- Allen JT, et al. Needs assessment of menopause education in United States obstetrics and gynecology residency training programs. Menopause. 2023. doi:10.1097/GME.0000000000002234. Survey finding only 31.3% of responding programs had a menopause curriculum.
- Makary MA, Nguyen CP, Hoeg TB, Tidmarsh GF. Updated labeling for menopausal hormone therapy. JAMA. Published online November 10, 2025. — and U.S. Food and Drug Administration. Labeling changes to clarify benefit/risk for menopausal hormone therapies. November 10, 2025. FDA removal of the boxed ("black box") warning from systemic estrogen products.